Continued capital market volatility, coupled with a costly, tightening, and oftentimes burdensome debt landscape, has driven royalty monetization transactions into the mainstream as life sciences companies increasingly seek...more
10/6/2025
/ Biotechnology ,
Capital Markets ,
Capital Raising ,
Financing ,
Investment Funds ,
Investors ,
Life Sciences ,
Monetization ,
Pharmaceutical Industry ,
Private Equity ,
Research and Development ,
Royalties